Dapagliflozin


 The CADTH Formulary Management Expert Committee (FMEC) concluded there was an unmet need to reduce the progression of chronic kidney disease (CKD), especially for those patients without diabetes, given lack reimbursed options.
 Evidence from DAPA-CKD trial, largest trial with longest follow-up identified by a systematic review, demonstrated that CKD treated dapagliflozin had slower decline estimated glomerular filtration rate, reduction in urinary albumin creatinine ratio, and increased time cardiovascular renal events compared placebo.
 FMEC reimbursement should be restricted eligible which included meeting diagnostic criteria treatment angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker at maximum-tolerated dose.